Kristijan H Kahler

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration
    Kristijan H Kahler
    Center for Health Care Knowledge and Management, VA New Jersey Health Care System, East Orange, New Jersey, USA
    Diabetes Care 30:1689-93. 2007
  2. pmc Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity
    Karina Raimundo
    Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 1080, USA
    BMC Health Serv Res 13:131. 2013
  3. pmc Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
    Jay M Margolis
    Thomson Reuters, 332 Bryn Mawr Ave, Bala Cynwyd, PA 19004, USA
    BMC Neurol 11:122. 2011
  4. ncbi request reprint Consequences of poor compliance with bisphosphonates
    Becky A Briesacher
    University of Massachusetts Medical School, Division of Geriatric Medicine, Biotech Four, Worcester, MA 01605, USA
    Bone 41:882-7. 2007

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration
    Kristijan H Kahler
    Center for Health Care Knowledge and Management, VA New Jersey Health Care System, East Orange, New Jersey, USA
    Diabetes Care 30:1689-93. 2007
    ....
  2. pmc Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity
    Karina Raimundo
    Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 1080, USA
    BMC Health Serv Res 13:131. 2013
    ..The purpose of this study was to identify high relapse activity (HRA) in patients with MS, comparing differences in outcomes between patients with and without HRA...
  3. pmc Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
    Jay M Margolis
    Thomson Reuters, 332 Bryn Mawr Ave, Bala Cynwyd, PA 19004, USA
    BMC Neurol 11:122. 2011
    ....
  4. ncbi request reprint Consequences of poor compliance with bisphosphonates
    Becky A Briesacher
    University of Massachusetts Medical School, Division of Geriatric Medicine, Biotech Four, Worcester, MA 01605, USA
    Bone 41:882-7. 2007
    ..This study was undertaken to assess rates of osteoporotic fractures and health care utilization as a function of bisphosphonate compliance in usual clinical practice...